<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lutropin alfa (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lutropin alfa (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lutropin alfa (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11389" href="/d/html/11389.html" rel="external">see "Lutropin alfa (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867417"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Luveris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F190577"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin;</li>
<li>
                        Ovulation Stimulator</li></ul></div>
<div class="block doa drugH1Div" id="F190566"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Follow current clinical practice to reduce the risk of ovarian hyperstimulation syndrome (OHSS); if OHSS occurs, initiate appropriate treatment and discontinue gonadotropin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27678032','lexi-content-ref-29080733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27678032','lexi-content-ref-29080733'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bfdb6205-015c-4e01-8046-705ba7f80ec7">Infertility, ovulation induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infertility, ovulation induction:</b>
<b>SUBQ:</b> 75 units daily until adequate follicular development is noted (maximum daily dose: 75 units/day); maximum duration of treatment: 14 days, unless signs of imminent follicular development are present. Duration of stimulation may be extended in any one cycle up to 5 weeks (treatment should be individualized based on response to prior cycle). Administer concomitantly with follitropin alfa. Administer hCG one day after the last dose of lutropin alfa and follitropin alfa.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992107"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989346"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F190541"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (3% to 19%), pain (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ovarian cyst (3% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (≤16%), abdominal pain (7% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (18%), mastalgia (7% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ovarian hyperstimulation (≤9%), ovarian disease (3% to 6%), increased serum cholesterol (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (3% to 9%), constipation (4% to 7%), diarrhea (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (4%), increased serum AST (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Accidental injury, acne vulgaris, anaphylaxis, anxiety, back pain, breast hypertrophy, conjunctivitis, cough, dental caries, depression, dizziness, drowsiness, dyspnea, dysuria, ectopic pregnancy, edema, endometrium disease, enlargement of abdomen, fever, flu-like symptoms, genital edema, hemorrhage (in pregnancy), herpes simplex infection, hyperkinesia, hypersensitivity reaction, infection, insomnia, Klebsiella species, leg cramps, leg pain, leukorrhea, malaise, nail disease, nervousness, ovarian hyperstimulation syndrome, ovary enlargement, pelvic congestion syndrome, pelvic pain, pharyngitis, porphyria, premenstrual syndrome, rhinitis, shock, skeletal pain, skin rash, spontaneous abortion, thromboembolism, urination disorder (change in frequency), uterine disease, uterine spasm, vaginal hemorrhage, vaginitis, vasodilation, vomiting, vulvovaginal candidiasis, weakness, xeroderma</p></div>
<div class="block coi drugH1Div" id="F190553"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to lutropin alfa or any component of the formulation; primary ovarian failure; uncontrolled thyroid or adrenal dysfunction; active, untreated tumors of the hypothalamus and pituitary gland; ovarian, uterine, or breast cancer; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement unrelated to polycystic ovarian disease and of undetermined origin; malformations of sexual organs incompatible with pregnancy; fibroid tumors of the uterus incompatible with pregnancy; pregnancy; breastfeeding</p></div>
<div class="block war drugH1Div" id="F190539"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ectopic pregnancy: Risk for ectopic pregnancy may be increased in patients with tubal abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian enlargement: Mild or moderate uncomplicated ovarian enlargement may be accompanied by abdominal distention or abdominal pain in patients treated with gonadotropins. This generally regresses without treatment within 2 to 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian hyperstimulation syndrome: Ovarian hyperstimulation syndrome (OHSS) is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Mild/moderate signs/symptoms of OHSS may include abdominal distention/discomfort, diarrhea, nausea, and mild/moderate enlargement of ovaries/ovarian cysts; severe signs/symptoms of OHSS may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, hydrothorax, nausea/vomiting (intractable), pleural effusion, rapid weight gain, venous thrombosis, and large ovarian cysts. Decreased CrCl, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: In association with and separate from OHSS, thromboembolic events have been reported. Risk may be increased in patients with thromboembolic disease or risk factors for thromboembolic events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Gonadotropins may increase the risk of an acute porphyric attack in patients with porphyria or a family history of porphyria; discontinuation of therapy may be necessary with onset or worsening of condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To minimize risks, use only at the lowest effective dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple births: Multiple births may result from use; advise patients of the potential risk of multiple births before starting the treatment. Discontinuation of therapy is recommended if there is a high risk for multiple pregnancies. Consider discontinuing or converting to assisted reproductive technology if &gt;2 follicles are mature prior to triggering ovulation.</p></div>
<div class="block prod-avail drugH1Div" id="F26122479"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040730"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block dinfoc drugH1Div" id="F52867418"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luveris: 75 units (1 ea)</p></div>
<div class="block adm drugH1Div" id="F190550"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syringe with follitropin alfa. Refer to manufacturer labeling for instructions on how to use lutropin alfa prefilled syringe.</p></div>
<div class="block use drugH1Div" id="F190549"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infertility, ovulation induction:</b> Stimulation of follicular development in patients with hypogonadotropic hypogonadism who have profound luteinizing hormone deficiency (&lt;1.2 units/L); to be used in combination with follitropin alfa.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Safety and efficacy have not been established for patients &lt;16 and &gt;60 years of age.</p></div>
<div class="block cyt drugH1Div" id="F13299623"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221384"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F54127934"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Possible contraindications to pregnancy should be evaluated prior to use. Lutropin alfa is contraindicated for use in patients who have medical conditions which are incompatible with a normal pregnancy. The rate of positive pregnancy tests and clinical pregnancies were increased in patients with hypogonadotropic hypogonadism administered lutropin alfa plus follitropin alfa, compared to patients receiving follitropin alfa and placebo (Dhillon 2008).</p></div>
<div class="block pri drugH1Div" id="F190554"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Ectopic pregnancy, miscarriage, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after assisted reproductive techniques than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics).</p></div>
<div class="block brc drugH1Div" id="F26122460"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lutropin alfa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Use is contraindicated in patients who are breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F190546"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to initiation of therapy, a thorough gynecologic and endocrinologic evaluation must be performed; pregnancy should be ruled out. Confirm that luteinizing hormone &lt;1.2 units/L.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor serum estradiol levels as well as follicular growth by transvaginal ultrasound to determine adequate ovarian response and timing of human chorionic gonadotropin (hCG) administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs and symptoms of ovarian hyperstimulation syndrome (OHSS) for at least 2 weeks following hCG administration. Initial symptoms of moderate to severe OHSS may include a sensation of bloating, abdominal pain, rapid weight gain, and decreased urine output (Shmorgun 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Ovarian hyperstimulation syndrome: Monitoring of hospitalized patients should include serum albumin, degree of ascites, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, hydration status, serum creatinine, urine output, urine-specific gravity, signs of thromboembolism, vital signs, weight (daily or as necessary), and liver enzymes (weekly) (Shmorgun 2017).</p></div>
<div class="block pha drugH1Div" id="F190538"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lutropin alfa is a recombinant luteinizing hormone prepared using Chinese hamster cell ovaries. Administration leads to increased follicular estradiol secretion needed for follicle stimulating hormone induced follicular development.</p></div>
<div class="block phk drugH1Div" id="F190552"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: 10 to 14 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 56%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: 21 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 9 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;5% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F190555"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Luver i.s.</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Luveris</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman, et al. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi:10.1016/S1701-2163(15)30417-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18627209">
<a name="18627209"></a>Dhillon S, Keating GM. Lutropin alfa. <i>Drugs</i>. 2008;68(11):1529-1540. doi:10.2165/00003495-200868110-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/18627209/pubmed" id="18627209" target="_blank">18627209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531097">
<a name="22531097"></a>Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi:10.1186/1477-7827-10-32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/22531097/pubmed" id="22531097" target="_blank">22531097</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Luveris (lutropin alfa) [product monograph]. Mississauga, Ontario, Canada: EMD Serono, A Division of EMD Inc, Canada; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi:10.1016/j.fertnstert.2016.08.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29080733">
<a name="29080733"></a>Shmorgun D, Claman P. No-268-The diagnosis and management of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2017;39(11):e479-e486. doi:10.1016/j.jogc.2017.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/29080733/pubmed" id="29080733" target="_blank">29080733</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10239 Version 103.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
